Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › VERA

Vera Therapeutics

VERA Rare disease Lead: Approved 8 Biotech Distilled articles ↓ 27 filings & releases ↓ Cash $55.3M (Sep 30, 2026) ↓ 8 verdicts ↓ 5 timing quotes ↓
Infectious DiseaseRenal Protein

Market cap $2.15B 72.3M shares (10-Q, Oct 29, 2026) × $29.79 close Nov 6, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Atacicept PIONEER Ph2 readout4Q 2026Atacicept PIONEER Ph2 readout, 4Q 2026, notable
  2. Oxford loan corporate updateMar 31, 2027Oxford loan corporate update, Mar 31, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Capital (as filed)

Cash
$55.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$329M Sep 30, 2026
Operating cash flow
−$99.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$384M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Vera Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2025-12-16 Watch Vera Therapeutics (VERA): Scientific Due Diligence for Atacicept and Pipeline Phase 3 data is real and M&A appeal is high, but the post-Phase-3 pop and dilutive financing may have priced in the easy money, warranting a watch with buy interest only on dips below the offering price.
  2. 2026-01-07 Hold UPDATE: Vera Therapeutics (VERA) Hits the Accelerator – FDA Grants Priority Review FDA Priority Review acceptance confirms the data package and tightens the regulatory timeline, solidifying first-mover advantage; holders should sit tight for the July PDUFA while sidelined investors wait for volatility to settle before building a position.
  3. 2026-02-28 Hold UPDATE: Vera Therapeutics (VERA) - FY25 Wrap-Up Strong $714M cash balance de-risks the commercial launch timeline through the July PDUFA; fundamentals tracking well but the primary label is HOLD with accumulation only on market-driven dips.
  4. 2026-03-07 Hold UPDATE: Vera Therapeutics (VERA) - VERA Adds an M&A Heavyweight to the Board Appointment of career dealmaker Christopher Hite to the board reinforces the M&A thesis; stance unchanged as holders wait for the July PDUFA binary event.
  5. 2026-06-02 Buy core UPDATE: Vera Therapeutics (VERA) - The Full Approval Clock Just Moved Up a Year FDA alignment to pull the confirmatory eGFR readout forward to Q3 2026 shortens the full-approval path by a year and widens the first-mover window against Vertex, while shares at $31.26 sit well below the $42.50 institutional offering price, making the setup into the July PDUFA and Q3 eGFR readout more attractive.
  6. 2026-07-07 Buy core UPDATE: Vera Therapeutics (VERA) - The Lazarus Drug Gets Its Label FDA granted accelerated approval to TRUTAKNA on the exact PDUFA date with no AdCom and no safety restrictions, validating the first-mover thesis; the 2-3 year monotherapy window against Vertex opens today and the Q3 eGFR readout remains the next asymmetric catalyst.
  7. 2026-08-11 Buy core UPDATE: Vera Therapeutics (VERA) - The Post-Approval Hangover Despite the approval pop fully reversing on burn acceleration and absent M&A bid, nothing in the filing breaks the thesis; at $31.58 the market has priced out the approval entirely while the imminent Q3 eGFR readout is the last genuinely asymmetric scientific catalyst, warranting accumulation ahead of it.
  8. 2026-09-16 Buy core UPDATE: Vera Therapeutics (VERA) - The Confirmatory Data Lands, and It's Not Close ORIGIN 3 final analysis delivered a flat eGFR slope (-0.6 vs -5.6 mL/min/year placebo), 76% reduction in composite kidney progression, and zero dialysis/transplant/death events on drug, retiring all remaining clinical binary risk and leaving only commercial execution and the royalty stack as outstanding risks.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (5 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (27)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)